Volume 14, Issue 2 (Mar-Apr 2020)                   mljgoums 2020, 14(2): 36-41 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

barari A, Dehghani pour F, abdi A, farzanegi P. Effects of Aerobic Exercise and Resveratrol Supplementation on Plasma Level and Liver Expression of Activin A and Follistatin in a Rats with Nonalcoholic Fatty liver Disease. mljgoums. 2020; 14 (2) :36-41
URL: http://mlj.goums.ac.ir/article-1-1228-en.html
1- Department of Sport Physiology , Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran , alireza54.barari@gmail.com
2- PhD Student, Ayatollah Amoli Branch, Islamic Azad University, Amol
3- Department of Sport Physiology , Ayatollah Amoli Branch, Islamic Azad University, Amol, Iran
4- Department of Sport Physiology, sari Branch, Islamic Azad University, sari
Abstract:   (1754 Views)
Background and objectives: Nonalcoholic fatty liver disease (NAFLD) is a chronic hepatic disease characterized by fat accumulation inside hepatocytes. The aim of this study was to evaluate effects of exercise training and resveratrol supplementation on activin A and follistatin levels in rats with NAFLD under a high-fat diet.
Methods: Fifty-six old (40-50 weeks) male Wistar rats were assigned to a healthy control group and seven experimental NAFLD groups: 1. high-fat diet, 2. saline, 3. resveratrol supplementation, 4. continuous exercise, 5. interval exercise, 6. continuous exercise+ resveratrol supplementation and 7. interval exercise+ resveratrol supplementation. Rats in the resveratrol supplementation groups were given 25 mg/kg of body weight intraperitoneal injection of resveratrol daily. Exercises were performed five days a week for eight weeks. Data were analyzed with SPSS (version 21) using one-way analysis of variance (ANOVA) and Tukey's post hoc test at significance of 0.05.
Results: Exercise training and resveratrol supplementation significantly decreased plasma activin A level and increased activin A expression (P<0.05). Plasma level of follistatin was significantly higher in rats under a high-fat diet compared to healthy control animals. All exercise and supplementation groups alone and combined lowered follistatin levels. However, follistatin mRNA expression increased significantly after resveratrol supplementation alone, continuous exercise+ resveratrol supplementation, and interval exercise+ resveratrol supplementation.
Conclusion: Resveratrol has a beneficial effect on activin A and follistatin levels in rats with NAFLD. In addition, resveratrol supplementation combined with exercise training may have greater health benefits for NAFLD patients compared to resveratrol supplementation or exercise training alone.
Keywords: Exercise, Resveratrol, Activin A, Follistatin, Nonalcoholic Fatty Liver Disease.
Full-Text [PDF 603 kb]   (259 Downloads)    
Research Article: Original Paper | Subject: Sport Physiology
Received: 2019/07/3 | Accepted: 2019/08/21 | Published: 2020/03/12 | ePublished: 2020/03/12

1. Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016; 65:1151-60. [DOI:10.1016/j.metabol.2016.01.010]
2. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl): S47-64. doi: 10.1016/j.jhep.2014.12.012. [DOI:10.1016/j.jhep.2014.12.012]
3. Polyzos SA, Kountouras J, Zavos C, Deretzi G. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol. 2012; 46(4): 272-84. doi: 10.1097/MCG.0b013e31824587e0.. [DOI:10.1097/MCG.0b013e31824587e0]
4. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013; 58(3): 593-608. doi: 10.1016/j.jhep.2012.12.005. [DOI:10.1016/j.jhep.2012.12.005]
5. Farrell G, Wong VW-S, Chitturi S. NAFLD in Asia - as common and important as in the West. Nat Rev Gastroenterol Hepatol. 2013; 10(5): 307-18. doi: 10.1038/nrgastro.2013.34. [DOI:10.1038/nrgastro.2013.34]
6. Pugh CJ, Sprung VS, Kemp GJ, Richardson P, Shojaee-Moradie F, Umpleby AM, et al. Exercise training reverses endothelial dysfunction in nonalcoholic fatty liver disease. Am J Physiol-Heart CircPhysiol 2014; 307(9): 1298-306. DOI:10.1152/ajpheart.00306.2014. [DOI:10.1152/ajpheart.00306.2014]
7. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut. 2007; 56 (12): 1760-9. DOI:10.1136/gut.2006.112094. [DOI:10.1136/gut.2006.112094]
8. George SA, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effect of physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009; 50(1): 68-76. doi: 10.1002/hep.22940. [DOI:10.1002/hep.22940]
9. Brown VA1, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res. 2010; 70(22): 9003-11. doi: 10.1158/0008-5472.CAN-10-2364. [DOI:10.1158/0008-5472.CAN-10-2364]
10. Gómez-Zorita S, Fernández-Quintela A, Macarulla MT, Aguirre L, Hijona E, Bujanda L, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012; 107(2): 202-10. doi: 10.1017/S0007114511002753. [DOI:10.1017/S0007114511002753]
11. Baek SH, Shin WC, Ryu HS, Lee DW, Moon E, Seo CS, et al. Creation of resveratrol-enriched rice for the treatment of metabolic syndrome and related diseases. PLoS One. 2013; 8(3): e57930. doi: 10.1371/journal.pone.0057930. [DOI:10.1371/journal.pone.0057930]
12. Kim S, Jin Y, Choi Y, Park T. Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem Pharmacol. 2011; 81(11): 1343-51. doi: 10.1016/j.bcp.2011.03.012. [DOI:10.1016/j.bcp.2011.03.012]
13. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with non-alcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12(12): 2092-103.e1-6. doi: 10.1016/j.cgh.2014.02.024. [DOI:10.1016/j.cgh.2014.02.024]
14. Yndestad A, Haukeland JW, Dahl TB, Halvorsen B, Aukrust P. Activin A in nonalcoholic fatty liver disease. Vitam Horm. 2011; 85: 323-42. doi: 10.1016/B978-0-12-385961-7.00015-9. [DOI:10.1016/B978-0-12-385961-7.00015-9]
15. Ding ZY, Jin GN, Wang W, Sun YM, Chen WX, Chen L, et al. Activin A-Smad signaling mediates connective tissue growth factor synthesis in liver progenitor cells. Int J Mol Sci. 2016; 17(3): 408. doi: 10.3390/ijms17030408. [DOI:10.3390/ijms17030408]
16. Phillips DJ, de Kretser DM. Follistatin: a multifunctional regulatory protein. Frontiers in Neuroendocrinology. 1998; 19(4): 287-322. DOI:10.1006/frne.1998.0169. [DOI:10.1006/frne.1998.0169]
17. Hedger MP, de Kretser DM. The activins and their binding protein, follistatin-diagnostic and therapeutic targets in inflammatory disease and fibrosis. Cytokine Growth Factor Rev. 2013; 24(3): 285-95. doi: 10.1016/j.cytogfr.2013.03.003.. [DOI:10.1016/j.cytogfr.2013.03.003]
18. Efati M, Khorrami M, ZareiMahmmodabadi A, RaoufSarshoori J. Induction of an Animal Model of Non-Alcoholic Fatty Liver Disease Using a Formulated High-Fat Diet. J BabolUniv Med Sci. 2016; 18(11): 57-62.
19. Berzigotti A, Saran U, Dufour JF. Physical activity and liver diseases. Hepatology. 2016; 63(3): 1026-40. doi: 10.1002/hep.28132. [DOI:10.1002/hep.28132]
20. Polyzos SA, Kountouras J, Anastasilakis AD, Triantafyllou GΑ, Mantzoros CS. Activin A and follistatin in patients with nonalcoholic fatty liver disease Metab. Metabolism. 2016; 65(10): 1550-8. doi: 10.1016/j.metabol.2016.07.009. [DOI:10.1016/j.metabol.2016.07.009]
21. Xia Y, Schneyer AL. The biology of activin: recent advances in structure, regulation and function. J Endocrinol. 2009; 202(1):1-12. doi: 10.1677/JOE-08-0549.. [DOI:10.1677/JOE-08-0549]
22. De Bleser PJ, Niki T, Xu G, Rogiers V, Geerts A. Localizationand cellular sources of activins in normal and fibrotic ratliver. Hepatology. 1997; 26: 905-12. [DOI:10.1002/hep.510260416]
23. Rodgarkia-Dara C, Vejda S, Erlach N, Losert A, Bursch W, Berger W, et al. The activin axis in liver biology and disease. Mutat Res. 2006; 613(2-3): 123-37. [DOI:10.1016/j.mrrev.2006.07.002]
24. Loureiro JA, Andrade S, Duarte A, Neves AR, Queiroz JF, Nunes C. Pereira, Resveratrol and grape extractloaded solid lipid nanoparticles for the treatment of Alzheimer's disease. Molecules. 2017; 22(2). pii: E277. doi: 10.3390/molecules22020277. [DOI:10.3390/molecules22020277]
25. Andrade JM, Paraíso AF, de Oliveira MV, Martins AM, Neto JF, Guimarães AL. Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 2014; 30(7-8): 915-9. doi: 10.1016/j.nut.2013.11.016. [DOI:10.1016/j.nut.2013.11.016]
26. Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015; 47(3): 226-32. doi: 10.1016/j.dld.2014.11.015. [DOI:10.1016/j.dld.2014.11.015]
27. Katsagoni CN, Georgoulis M, Papatheodoridis GV, Panagiotakos DB, Kontogianni MD. Effects of lifestyle interventions on clinical characteristics of patients with non-alcoholic fatty liver disease: A meta-analysis. Metabolism. 2017; 68: 119-132. doi: 10.1016/j.metabol.2016.12.006.. [DOI:10.1016/j.metabol.2016.12.006]
28. Colberg SR, Sigal RJ, Yardley JE, Riddell MC, Dunstan DW, Dempsey PC, et al. Physical activity/exercise and diabetes: A position statement of the American Diabetes Association. Diabetes Care 2016; 39(11): 2065-2079. [DOI:10.2337/dc16-1728]
29. Marchesini G, Petta S, Dalle Grave R. Diet, weight loss, and liver health in NAFLD: Pathophysiology, evidence and practice. Hepatology. 2016; 63(6): 2032-43. doi: 10.1002/hep.28392. [DOI:10.1002/hep.28392]
30. Oh S, So R, Shida T, Matsuo T, Kim B, Akiyama K, et al. High-intensity aerobic exercise improves both hepatic fat content and stiffness in sedentary obese men with nonalcoholic fatty liver disease. Sci Rep. 2017; 7: 43029. doi: 10.1038/srep43029. [DOI:10.1038/srep43029]
31. Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am J Gastroenterol. 2011; 106(3): 460-8; quiz 469. doi: 10.1038/ajg.2010.488. [DOI:10.1038/ajg.2010.488]
32. Silva RN, Bueno PG, Avo LR, Nonaka KO, Selistre-Araujo HS, Leal AM. Effect of physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver disease model in rats. Braz J Med Biol Res. 2014; 47(9): 746-752. [DOI:10.1590/1414-431X20143869]
33. Polyzos SA, Kountouras J, Anastasilakis AD, Triantafyllou GΑ, Mantzoros CS. MantzorosActivin A and follistatin in patients with nonalcoholic fatty liver disease. Metabolism. 2016; 65(10): 1550-8. doi: 10.1016/j.metabol.2016.07.009. [DOI:10.1016/j.metabol.2016.07.009]
34. Phillips DJ, Jones KL, Scheerlinck JY, Hedger MP, de Kretser DM. Evidence for activin A and follistatin involvement in the systemic inflammatory responses. Mol Cell Endocrinol. 2001; 180(1-2): 155-62. [DOI:10.1016/S0303-7207(01)00516-0]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2007 All Rights Reserved | Medical Laboratory Journal